Browse
Popular
Books and Audio
Eurocel
180 Caps.
Supports liver health and improves quality of sleep, increases energy levels, and promotes softer skin.
Regular: $149.00
$106.10 Your Price!
Immune Power
120 Tablets
Promotes rapid cellular repair, increases energy, enhances brain function, and helps boost the immune system.
Regular: $38.00
$29.50 Your Price!
L-Citrulline
Powder, 100 grams.
Supports the body in optimizing blood flow and alleviates mental and physical fatigue.
Regular: $44.00
$33.00 Your Price!
Stabilium
30 Gel Caps.
Supports healthy sleep, provides energy, and enhances memory and mood.
Regular: $23.65
$17.70 Your Price!
Enada 5.0
NADH dietary supplement that provides an increase in energy, vitality, and mental activity.
SKU: ENA5.0
Regular Price: $35.00
Sale Price: $25.00
(per unit)
ENADA® is the world's first and only NADH dietary supplement that is now available to everyone whose lifestyle demands more energy, vitality and mental activity.
NADH, biologically known as Coenzyme 1, is the reduced form of nicotinamide adenine dinucleotide (NAD) with high energy hydrogen (H) which provides energy to the cell. NADH is necessary for thousands of biochemical reactions within the body and is found naturally in every living cell. NADH plays a key role in the energy production of cells, particularly in the brain and central nervous system. The more NADH a cell has available, the more energy it can produce to perform its process efficiently.
ENADA is used for some of the following conditions:
Fibromyalgia symptoms
Enhances Energy Naturally!
Memory
Chronic Fatigue Syndrome
STUDY ABSTRACT
THE MEASUREMENT OF 5-HIAA URINARY CONCENTRATION AS A POSSIBLE PREDICTIVE
MARKER OF DISEASE ACTIVITY AND THERAPEUTIC EFFICACY OF NADH IN THE CHRONIC
FATIGUE SYNDROME.
Joseph A Bellanti MD; Linda M Forsyth MD; Ana Luiza
MacDowell-Carneiro MD; Dawn B. Wallerstedt, MSN, FNP; Harry G
Preuss MD2 and Georg D Birkmayer MD. PhD3
From the Departments of Pediatrics and Microbiology-Immunology and the International Center for Interdisciplinary Studies of Immunology1 and the Department of Medicine, Division of Nephrology2, Georgetown University Medical Center, Washington, DC; and Birkmayer Pharmaceuticals3, Vienna, Austria.
Background: Chronic fatigue syndrome (CFS) is a disorder of unknown etiology characterized by prolonged, severe fatigue that persists six months or greater in duration and by a multitude of symptoms including neurocognitive dysfunction, flu-like symptoms, myalgia, muscle weakness, arthralgia, low-grade fever, sore throat, headaches sleep disturbances and swelling and tenderness of the lymph nodes. We have recently demonstrated the clinical effectiveness of reduced nicotinamide adenine dinucleotide (NADH) in a group of 26 patients with CFS in a double-blinded, placebo-controlled, crossover study.
Objective: The overall goal of the present study was to extend our initial observations of the clinical efficacy of NADH in CFS to the measurement of a spectrum of biochemical neurotransmitter metabolites which might serve as predictive marker(s) of disease activity. Plasma concentrations of norepinephrine, dopamine and serotonin as well as urinary metabolites, 5-hydroxyindole acetic acid (5-HIAA) and homovanillic acid (HVA) were measured.
Methods: Ten of the originally reported patients with CFS were evaluated. Plasma concentrations of the norepinephrine metabolite MHPG and urinary concentrations of the serotonin and dopamine metabolites, 5-HIAA and HVA, respectively, were measured and the results were analyzed and correlated with treatment of subjects with NADH or placebo.
Results: No significant changes in plasma metabolites were observed. In contrast, baseline values of urinary concentrations of 5-HIAA were elevated (>2mgfL) prior to NADH or placebo in 15/20 (75%) of patient-paired-sample measurements. Following NADH treatment these elevated 5-HIAA concentrations returned to the normal range (<2mg/L) in 7/10(70%) of subjects receiving NADH and in 3/10 (30%) of subjects receiving placebo. The mean negative change in urinary 5-HIAA concentration over the 4 week treatment period was -3.41 in NADH-treated subjects vs. -1.92 in placebo-treated subjects; the mean positive change in urinary 5-HIAA concentration over the 4 week period was +0.17 in the NADH-treated subjects vs. +4.73 in the placebo-treated group (p<0.05).
Conclusions: The results of these preliminary studies not only suggest that NADH is a safe naturally occurring biological substance which may be a useful therapeutic adjunct in the management of the chronic fatigue syndrome, but also that the measurement of urinary 5-HIAA may serve both as an important predictive marker of disease activity as well as an objective marker of improvement following NADH therapy.
Regular Price: $35.00
Sale Price: $25.00 (per unit)
Books & Tapes | Grocery Patrol | It's Your Body | Whats Cookin? | Our Privacy Policy | Shipping | What's New? | Suggested Links
Springboard products which are foods and/or foods for special dietary use, are not offered for the diagnosis, cure, mitigation, treatment, or prevention of any disease or disorder nor have any statements herein been evaluated by the Food and Drug Administration. We strongly encourage you to discuss topics of concern with your health care professional.
©2009 Springboard 4 Health